Fabentech
French tech company | Builders Republic
About
Biopharmaceutical company developing and manufacturing polyclonal antibody-fragment immunotherapies for medical emergencies — from avian flu and Ebola to biothreat antidotes for defence agencies, produced at its own bioproduction site in Lyon.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Series C
- Founded
- 2009
- City
- LYON
- Region
- Auvergne-Rhône-Alpes
- Tracked rounds
- 2
- Amount raised
- 14 M€
Operations
- Series C · 2020
- Series B · 2014
Investors
- Auriga Partners
- Bpifrance Deeptech Venture
- Elaia Partners
- Institut Mérieux
- R2V
- Rhône-Alpes Création
- Sigma Gestion
- UI Investissement